The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts
Authors
Keywords
CXCL1, Chemokine, CRC prognosis, KRAS, Tumor microenvironment
Journal
Journal of Translational Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-06-23
DOI
10.1186/s12967-015-0555-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MMP3 and CXCL1 are potent stromal protein markers of dysplasia–carcinoma transition in sporadic colorectal cancer
- (2014) Ferenc Sipos et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Differential gene expression of chemokines inKRASandBRAFmutated colorectal cell lines: Role of cytokines
- (2014) Sajjad Khan WORLD JOURNAL OF GASTROENTEROLOGY
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-γ
- (2013) Savvas Petanidis et al. PLoS One
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue
- (2011) O Oladipo et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis
- (2011) Obul R. Bandapalli et al. CYTOKINE
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)
- (2011) Dongxu Sun et al. NATURE IMMUNOLOGY
- Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases
- (2010) Michelle L. Varney et al. CANCER LETTERS
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis
- (2009) Kevin M. O'Hayer et al. CARCINOGENESIS
- ELR+ CXC chemokine expression in benign and malignant colorectal conditions
- (2008) Claudia Rubie et al. BMC CANCER
- Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence
- (2008) Juan C. Acosta et al. CELL
- Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics
- (2008) B. B. Ancrile et al. MOLECULAR INTERVENTIONS
- Stromal gene expression predicts clinical outcome in breast cancer
- (2008) Greg Finak et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started